[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100418584":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":50,"collaborators":19,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":19,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":19,"enrollmentInfo":62,"targetDuration":19,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine","EXPERIMENTAL","IV administration of Dexmedetomidine, using an Up-Down method utilizing a biased coin design to determine that next patient's dose. Initial dose will be 10mcg.",[13],"Drug: Dexmedetomidine",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Doses of dexmedetomidine will be selected according to a sequential up-and-down method, using a biased coin design to find the estimated dose at which 90% of patients would have desired effect",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Hans Sviggum, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Hans P Sviggum, MD","CONTACT","507-293-1169","sviggum.hans@mayo.edu",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Mayo Clinic in Rochester","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-92.4699,44.02163,{"lat":43,"lon":42},[46],{"name":47,"role":27,"phone":48,"phoneExt":19,"email":49},"Mickelson Randa","507-284-9697","mickelson.randa@mayo.edu",{"type":23,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Hans P. Sviggum, M.D.","Principal Investigator","100418584","phase-4-dexmedetomidine-for-intraoperative-shivering-in-scheduled-elective-cesarean-delivery-100418584",false,"NCT04730609","Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery","Dexmedetomidine for Treatment of Shivering During Scheduled Elective Cesarean Delivery: Determining the Optimal Dose","Inclusion Criteria:\n\n* Women presenting for planned cesarean delivery.\n* American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.\n* Singleton gestation in the 3rd trimester (28-42 weeks gestation).\n* Spinal anesthesia technique Women presenting for planned cesarean delivery.\n* American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.\n* Singleton gestation in the 3rd trimester (28-42 weeks gestation).\n* Spinal anesthesia technique.\n\nExclusion Criteria:\n\n* Any contraindication to spinal anesthesia technique.\n* Allergy or intolerance to dexmedetomidine or clonidine.\n* Oral temperature \\\u003C 36° Celsius prior to procedure.\n* Unable to give personal consent.\n* PPROM or concern for infection (e.g., chorioamnionitis).\n* Conversion to General Anesthesia prior to randomization.\n* Sedative medications (e.g., fentanyl, midazolam, ketamine, nitrous oxide) administered prior to randomization.","FEMALE","18 Years",{"count":63,"type":64},40,"ESTIMATED","INTERVENTIONAL",[67],"PHASE4","The purpose of this study is to determine the optimum dose of Dexmedetomidine to stop shivering in 90% of patients who experience shivering during scheduled elective cesarean deliveries.",[70,71],"Shivering","Dose Finding Study",[70,73,9,74],"Cesarean Delivery","Dosing","2025-09-05",{"date":77,"type":78},"2025-09-11","ACTUAL",{"date":80,"type":78},"2021-09-21",{"date":82,"type":64},"2026-08",{"name":5,"class":6},1]